BioNixus is a specialist pharmaceutical and healthcare market research company serving Dubai, the wider UAE, and the GCC. Since 2012, we have been delivering physician surveys, hospital sales data, KOL mapping, and market access research for pharmaceutical, biotech, and MedTech companies operating in Dubai and across the MENA region.
Dubai is home to the MENA regional headquarters of many of the world's largest pharmaceutical companies — Pfizer, Roche, Novartis, AstraZeneca, Sanofi, and Johnson & Johnson all run their GCC and MENA operations out of Dubai Internet City and Dubai Healthcare City. These teams need a healthcare market research agency that understands both the local regulatory environment and the broader MENA market context.
Many healthcare market research agencies operating in Dubai subcontract their UAE physician recruitment to regional panel brokers, introducing quality and compliance risk. BioNixus maintains proprietary UAE physician panels verified against DHA, HAAD/DOH, and MOHAP registration databases. When you recruit 50 Dubai-based oncologists through BioNixus, you get 50 verified, licensed oncologists — not a blended panel with unverifiable credentials.
BioNixus collects UAE hospital sales data directly from pharmacy dispensing records, hospital procurement systems, and physician prescription data across Dubai's public and private hospital networks. This primary-source approach gives pharmaceutical clients actual dispensing behaviour — not modelled estimates — at patient level, indication level, department level, and hospital level.
Key institutions covered include Mediclinic City Hospital, American Hospital Dubai, NMC Health, Aster DM Healthcare, King's College Hospital Dubai, Rashid Hospital, Dubai Hospital, and the major Jumeirah-cluster private clinics.
A Dubai-based pharmaceutical market research study rarely stays in Dubai. Most GCC launch programmes require data and physician insights from Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman simultaneously. BioNixus operates with direct field infrastructure across all GCC markets from its MENA regional office in Cairo — meaning consistent methodology, unified data standards, and a single project manager across your entire MENA programme.
All BioNixus UAE physician surveys are available in Arabic (Modern Standard Arabic and Gulf dialect) as well as English. Our questionnaires are professionally translated and back-translated to maintain scientific rigour. CATI fieldwork is conducted by native Arabic-speaking interviewers.
BioNixus conducts all UAE pharmaceutical market research under ICH-GCP protocols, with GDPR-compliant data handling throughout. All physician participants provide informed consent. Ethics committee approval support is available for studies requiring institutional review in Dubai.
Understanding Dubai's healthcare regulatory architecture is essential for designing effective pharmaceutical market research in the emirate.
Regulates all healthcare facilities and licensed professionals within Dubai. Operates the Dubai Health Insurance framework and manages the public hospital network — Rashid Hospital, Dubai Hospital, Latifa Hospital, Al Wasl Hospital. BioNixus maintains physician panels across all DHA-regulated facilities.
The world's largest healthcare free zone — over 4,000 licensed professionals and 120+ clinical facilities including the Harvard Medical School Dubai Center. BioNixus has strong KOL relationships within DHCC across oncology, cardiology, and rare disease specialties.
Ministry of Health and Prevention governs pharmaceutical registration at the federal level across all UAE emirates. BioNixus's market access research includes MOHAP registration timeline analysis, pricing recommendations, and formulary inclusion strategy for public and private channels.
Dubai's pharma market is dominated by the private sector. Major groups — Mediclinic, NMC Health, Aster DM Healthcare, and boutique Jumeirah-cluster hospitals — operate their own formulary committees and procurement. BioNixus maps private sector payer dynamics and formulary decision-making.
| Service | Description | Typical Deliverable |
|---|---|---|
| UAE Physician Surveys | Quantitative surveys of 50–400 Dubai and UAE-registered physicians across all specialties. CATI, online panel, and face-to-face. | Topline and full data tables, crosstab analysis, executive summary |
| Dubai Hospital Sales Data | Primary-source sales data from pharmacy dispensing, hospital procurement, and physician prescription records across Dubai and the UAE. | Monthly or quarterly data feed, institution-level breakdown, trend analysis |
| Consumption Analytics | Patient-level, indication-level, department-level, and hospital-level consumption data — more granular than standard audit panels. | Consumption dashboard, launch tracking report, adherence analysis |
| KOL Mapping — UAE | Key opinion leader identification and influence scoring across Dubai and Abu Dhabi specialist centres. Publication analysis, congress activity, advisory board history. | Tiered KOL list (Tier 1–3), engagement strategy, influence heat map |
| UAE Market Access Research | MOHAP registration pathway analysis, private and public payer landscape, formulary decision-maker interviews, pricing benchmarking. | Market access dossier, pricing recommendation, payer map |
| Qualitative Research | In-depth interviews with Dubai-based KOLs, payer decision-makers, hospital directors, and pharmacy procurement leads. Arabic and English. | Verbatim transcripts, thematic analysis, strategic implications |
| GCC Multi-Country Studies | Dubai as hub for simultaneous research across UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, and Egypt — single vendor, unified methodology. | Country-by-country comparison report, GCC consolidated findings |
| Patient Journey Mapping | Diagnosis-to-treatment pathway analysis across Dubai's public and private healthcare settings. Switch behaviour, adherence patterns, care gaps. | Patient journey map, opportunity sizing, channel strategy |
BioNixus conducts pharmaceutical and healthcare industry market research in Dubai across all major therapeutic areas:
Pharmaceutical companies with Dubai-based MENA or GCC regional headquarters use BioNixus to commission physician surveys, sales data, and market access research across their territory — often in lieu of or to supplement global suppliers whose MENA coverage is limited.
UAE affiliate teams use BioNixus for rapid-turnaround quantitative physician studies (brand tracker, launch readiness, message testing) and qualitative KOL interviews — typically on a study-by-study basis without long-term contract commitments.
Pre-commercial biotech and MedTech companies preparing for UAE launch use BioNixus for landscape analysis, KOL identification, payer access mapping, and MOHAP registration readiness assessments.
Strategy consultancies and market access advisory firms use BioNixus as a primary data and fieldwork partner for UAE and GCC client engagements, providing physician survey data, sales analytics, and qualitative findings under white-label or co-branded arrangements.
Private equity and venture capital firms investing in UAE and GCC pharmaceutical or healthcare assets commission BioNixus for commercial due diligence — physician sentiment studies, market sizing, competitive benchmarking, and channel analysis.
BioNixus is a specialist pharmaceutical market research firm operating across Dubai and the wider UAE since 2012. We conduct quantitative physician surveys, hospital sales data collection, KOL mapping, and market access research for pharmaceutical, biotech, and MedTech companies with UAE and MENA operations. BioNixus works with clients based in Dubai Healthcare City, Dubai Internet City, and across the emirate's public and private hospital network, including DHA-regulated and MOHAP-registered facilities.
BioNixus serves Dubai pharmaceutical clients from its London UK office and MENA regional office in Cairo, with global project coordination from the US headquarters in Sheridan, Wyoming. While BioNixus does not maintain a physical Dubai office, our UAE physician panels, procurement data networks, and KOL relationships are built on over 12 years of direct in-market fieldwork — giving clients deeper access than many locally-registered agencies with limited MENA track records.
When selecting a healthcare market research agency in Dubai, verify: verified UAE physician panels (DHA, HAAD/DOH, MOHAP registration); ICH-GCP compliant fieldwork; Arabic-language survey capability; UAE hospital sales data experience; and GCC multi-country capability if your study covers the wider region. BioNixus meets all criteria with 12+ years of UAE pharmaceutical research experience. Contact us at admin@bionixus.com or call +44 7727 666682 (UK) / +1 888 465 5557 (US).
BioNixus provides the following pharmaceutical market research services in Dubai: quantitative physician surveys (50–400 UAE-registered physicians), qualitative KOL depth interviews, hospital sales data (pharmacy, procurement, and physician-sourced), consumption analytics at patient, indication, department and hospital level, KOL mapping, payer and market access research, patient journey studies, and GCC competitive intelligence.
For a GCC pharmaceutical launch study based out of Dubai, BioNixus offers single-vendor coverage across all six GCC markets — UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman — plus Egypt. Unified methodology across all markets, one point of contact, and project management across UK, US, and MENA time zones.
Yes. BioNixus has been conducting healthcare industry market research in Dubai since 2012 across all major therapeutic areas. UAE research covers both the DHA-regulated Dubai sector and the federal MOHAP framework, with physician panels across Mediclinic, NMC Health, American Hospital Dubai, Aster DM Healthcare, King's College Hospital Dubai, and the major public hospital network.